DK3185853T3 - Inhalerbare pulverformuleringer af alginatoligomerer - Google Patents
Inhalerbare pulverformuleringer af alginatoligomerer Download PDFInfo
- Publication number
- DK3185853T3 DK3185853T3 DK15763236.5T DK15763236T DK3185853T3 DK 3185853 T3 DK3185853 T3 DK 3185853T3 DK 15763236 T DK15763236 T DK 15763236T DK 3185853 T3 DK3185853 T3 DK 3185853T3
- Authority
- DK
- Denmark
- Prior art keywords
- alginatoligomers
- powder formulations
- inhalable powder
- inhalable
- formulations
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 239000000843 powder Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Otolaryngology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1415381.1A GB201415381D0 (en) | 2014-08-29 | 2014-08-29 | Inhalable powder formulations of alginate oligomers |
| PCT/EP2015/069785 WO2016030524A1 (en) | 2014-08-29 | 2015-08-28 | Inhalable powder formulations of alginate oligomers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3185853T3 true DK3185853T3 (da) | 2024-02-26 |
Family
ID=51752384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15763236.5T DK3185853T3 (da) | 2014-08-29 | 2015-08-28 | Inhalerbare pulverformuleringer af alginatoligomerer |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20180235879A1 (da) |
| EP (1) | EP3185853B1 (da) |
| JP (1) | JP6707076B2 (da) |
| KR (1) | KR102582982B1 (da) |
| CN (2) | CN113384538A (da) |
| AU (1) | AU2015308381B2 (da) |
| BR (1) | BR112017004048A2 (da) |
| CA (1) | CA2959101A1 (da) |
| DK (1) | DK3185853T3 (da) |
| ES (1) | ES2972433T3 (da) |
| FI (1) | FI3185853T3 (da) |
| GB (1) | GB201415381D0 (da) |
| RU (1) | RU2708397C1 (da) |
| WO (1) | WO2016030524A1 (da) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1993360T (pt) | 2005-12-28 | 2017-05-25 | Vertex Pharma | Formas sólidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-di-hidro-4-oxoquinolina-3-carboxamida |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| RU2569678C2 (ru) | 2010-04-22 | 2015-11-27 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения циклоалкилкарбоксамидо-индольных соединений |
| PT3131582T (pt) | 2014-04-15 | 2018-10-08 | Vertex Pharma | Composições farmacêuticas para o tratamento de doenças mediadas pelo regulador de condutância transmembranar da fibrose quística |
| EP3463378A4 (en) * | 2016-06-03 | 2020-01-08 | Otitopic Inc. | DRY POWDER FORMULAS FOR INHALATION |
| WO2018127819A1 (en) | 2017-01-03 | 2018-07-12 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto |
| GB201702161D0 (en) * | 2017-02-09 | 2017-03-29 | Algipharma As | A companion diagnostic method for use in the treatment of cystic fibrosis with alginate oligomers |
| WO2018178902A1 (en) | 2017-03-28 | 2018-10-04 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing polyaminoglycosides as biodegradable antibacterial scaffolds and methods pertaining thereto |
| US12460050B2 (en) | 2017-11-15 | 2025-11-04 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing hyperbranched compounds as antibacterial scaffolds and methods pertaining thereto |
| AU2019231712B2 (en) | 2018-03-06 | 2025-04-10 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto |
| CN111867634B (zh) * | 2018-03-19 | 2024-06-11 | 阿尔吉法玛公司 | 使用藻酸酯低聚物增强微米/纳米颗粒跨粘液层的易位 |
| CA3124673A1 (en) | 2018-12-28 | 2020-07-02 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing antibacterial polymers and scaffolds fabricated therefrom and methods pertaining thereto |
| CN111202723A (zh) * | 2020-02-15 | 2020-05-29 | 江苏艾立康药业股份有限公司 | 一种达芦那韦吸入干粉药物组合物及其制备方法 |
| WO2021183371A1 (en) * | 2020-03-11 | 2021-09-16 | Purdue Research Foundation | Nano-composite microparticles of polymyxin |
| CN113491678B (zh) * | 2020-04-07 | 2023-01-20 | 知和(山东)大药厂有限公司 | 一种盐酸阿比朵尔吸入剂及其制备方法 |
| US20230270672A1 (en) | 2020-08-07 | 2023-08-31 | Council For Scientific And Industrial Research | Microemulsion drug delivery system for treatment of acute respiratory distress syndrome |
| US20240252431A1 (en) * | 2021-07-20 | 2024-08-01 | Onconox Inc. | Pulmonary biguanide formulations and delivery devices |
| WO2023028354A1 (en) * | 2021-08-26 | 2023-03-02 | Celestial Therapeutics, Inc | Method for generating dry powder suitable for inhalation/intranasal/intratracheal administration of antimicrobial phospholipid compositions |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7221691A (en) | 1990-01-23 | 1991-08-21 | Terje Espevik | Mannuronic acid containing alginate wound healing composition and method |
| US5169840A (en) | 1991-03-27 | 1992-12-08 | Nobipols Forskningsstiftelse | Diequatorially bound β-1, 4 polyuronates and use of same for cytokine stimulation |
| NO305033B1 (no) | 1997-05-09 | 1999-03-22 | Algipharma As | Fremgangsmate for fremstilling av uronsyreblokker fra alginat |
| CA2352178A1 (en) * | 1998-12-08 | 2000-06-15 | Mathew Louis Steven Leigh | Phospholipid compositions |
| WO2000045878A2 (de) * | 1999-02-03 | 2000-08-10 | Max-Delbrück-Centrum für Molekulare Medizin | Druckluftinhalator zur pulmonalen applikation liposomalen pulver-aerosols sowie dafür geeignete pulver-aerosole |
| US6586008B1 (en) * | 1999-08-25 | 2003-07-01 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles during spray drying |
| NO326145B1 (no) | 2001-11-30 | 2008-10-06 | Fmc Biopolymer As | Fremgangsmate for a stimulere vektokning hos pattedyr, fugler og krypdyr. |
| AU2003221888B2 (en) * | 2002-04-11 | 2008-11-06 | Medimmune, Llc | Preservation of bioactive materials by spray drying |
| US20120321717A1 (en) * | 2003-04-14 | 2012-12-20 | Vectura Ltd. | Devices and pharmaceutical compositions for enhancing dosing efficiency |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| PL2489659T3 (pl) | 2004-06-24 | 2018-06-29 | Vertex Pharma | Modulatory transporterów posiadających kasetę wiążącą atp |
| GB0515492D0 (en) * | 2005-07-28 | 2005-08-31 | Reckitt Benckiser Healthcare | Improvements in or relating to compositions,articles and methods |
| GB2430881B (en) | 2005-10-06 | 2010-10-13 | Ntnu Technology Transfer As | Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity |
| DK2774925T3 (da) | 2005-11-08 | 2017-02-27 | Vertex Pharma | Heterocycliske modulatorer af ATP-bindings-kassettetransportere |
| JP2009536969A (ja) | 2006-05-12 | 2009-10-22 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミド組成物 |
| GB0613161D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| GB0707096D0 (en) | 2007-04-12 | 2007-05-23 | Ntnu Technology Transfer As | Method |
| BRPI0816345A2 (pt) | 2007-09-14 | 2015-02-24 | Vertex Pharma | Formas sólidas de n-[2,4-bis-(1,1-dimetiletil)-5-hidroxifenil]-1,4-diidro-4-o xoquinolin-3-carboxamida |
| EP2578571B1 (en) | 2007-11-16 | 2015-09-16 | Vertex Pharmaceuticals Incorporated | Isoquinoline modulators of ATP-binding cassette transporters |
| PT2268142T (pt) * | 2007-11-27 | 2017-06-02 | Algipharma As | Utilização de oligómeros alginados no combate aos biofilmes |
| CN103626744B (zh) | 2007-12-07 | 2016-05-11 | 沃泰克斯药物股份有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的固体形式 |
| US20100036130A1 (en) | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| AU2008335440B2 (en) | 2007-12-07 | 2013-11-07 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| AU2008335439A1 (en) | 2007-12-07 | 2009-06-18 | Vertex Pharmaceuticals Incorporated | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| WO2009094846A1 (en) * | 2007-12-28 | 2009-08-06 | Shanghai Institute Of Pharmaceutical Industry | Insulin nasal powder inhalation |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| KR20110042356A (ko) | 2008-08-13 | 2011-04-26 | 버텍스 파마슈티칼스 인코포레이티드 | 제약 조성물 및 그의 투여 |
| BRPI0919550A2 (pt) | 2008-09-29 | 2019-09-10 | Vertex Pharma | unidades de dosagem de ácido 3-(6-(1-(2,2-difluorobenzo]d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzoico |
| SI2349263T1 (sl) | 2008-10-23 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Modulatorji cistiäśno-fibroznega transmembranskega regulatorja prevodnosti |
| KR20160013251A (ko) | 2008-11-06 | 2016-02-03 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｐ-결합 카세트 수송자의 조절자 |
| UA104876C2 (uk) | 2008-11-06 | 2014-03-25 | Вертекс Фармасьютікалз Інкорпорейтед | Модулятори atф-зв'язувальних касетних транспортерів |
| RU2586253C2 (ru) | 2009-06-03 | 2016-06-10 | АльгиФарма АС | Обработка акинетобактерий альгинатными олигомерами и антибиотиками |
| MX2012004792A (es) | 2009-10-22 | 2013-02-01 | Vertex Pharma | Composiciones para el tratamiento de fibrosis quistica y otras enfermedades cronicas. |
| AR081069A1 (es) | 2010-04-07 | 2012-06-06 | Vertex Pharma | Formas solidas del acido 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico |
| EP2555755B2 (en) | 2010-04-07 | 2019-07-10 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof |
| NZ603043A (en) | 2010-04-22 | 2015-02-27 | Vertex Pharma | Pharmaceutical compositions comprising cftr modulators and administrations thereof |
| CA2796646A1 (en) | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| AU2011242452A1 (en) | 2010-04-22 | 2012-11-08 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| RU2569678C2 (ru) | 2010-04-22 | 2015-11-27 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения циклоалкилкарбоксамидо-индольных соединений |
| NZ603386A (en) | 2010-05-20 | 2015-02-27 | Vertex Pharma | Pharmaceutical compositions and administrations thereof |
| CN102302477B (zh) * | 2011-06-02 | 2013-08-28 | 张振海 | 一种华蟾酥毒基干粉吸入剂及其制备方法、应用 |
| US9682096B2 (en) * | 2012-05-02 | 2017-06-20 | Janssen R & D Ireland | Polyinosinic-polycytidylic acid (poly (I:C)) formulations for the treatment of upper respiratory tract infections |
| CN106029079A (zh) | 2014-02-28 | 2016-10-12 | 阿尔吉法玛公司 | 藻酸盐低聚物在治疗囊性纤维化和与缺陷性cftr离子通道功能相关的其它疾病中的应用 |
-
2014
- 2014-08-29 GB GBGB1415381.1A patent/GB201415381D0/en not_active Ceased
-
2015
- 2015-08-28 ES ES15763236T patent/ES2972433T3/es active Active
- 2015-08-28 WO PCT/EP2015/069785 patent/WO2016030524A1/en not_active Ceased
- 2015-08-28 CN CN202110642947.2A patent/CN113384538A/zh active Pending
- 2015-08-28 CN CN201580046086.4A patent/CN106659689B/zh active Active
- 2015-08-28 US US15/507,712 patent/US20180235879A1/en not_active Abandoned
- 2015-08-28 CA CA2959101A patent/CA2959101A1/en active Pending
- 2015-08-28 KR KR1020177006232A patent/KR102582982B1/ko active Active
- 2015-08-28 JP JP2017511704A patent/JP6707076B2/ja active Active
- 2015-08-28 AU AU2015308381A patent/AU2015308381B2/en active Active
- 2015-08-28 RU RU2017106950A patent/RU2708397C1/ru active
- 2015-08-28 DK DK15763236.5T patent/DK3185853T3/da active
- 2015-08-28 BR BR112017004048A patent/BR112017004048A2/pt not_active IP Right Cessation
- 2015-08-28 FI FIEP15763236.5T patent/FI3185853T3/fi active
- 2015-08-28 EP EP15763236.5A patent/EP3185853B1/en active Active
-
2021
- 2021-08-20 US US17/445,577 patent/US11992553B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN113384538A (zh) | 2021-09-14 |
| US20180235879A1 (en) | 2018-08-23 |
| US20210386666A1 (en) | 2021-12-16 |
| ES2972433T3 (es) | 2024-06-12 |
| AU2015308381B2 (en) | 2020-10-22 |
| CN106659689B (zh) | 2021-07-13 |
| CA2959101A1 (en) | 2016-03-03 |
| CN106659689A (zh) | 2017-05-10 |
| EP3185853A1 (en) | 2017-07-05 |
| KR102582982B1 (ko) | 2023-09-25 |
| JP2017530952A (ja) | 2017-10-19 |
| EP3185853B1 (en) | 2024-01-31 |
| AU2015308381A1 (en) | 2017-04-06 |
| WO2016030524A1 (en) | 2016-03-03 |
| FI3185853T3 (fi) | 2024-02-22 |
| BR112017004048A2 (pt) | 2017-12-05 |
| KR20170044670A (ko) | 2017-04-25 |
| GB201415381D0 (en) | 2014-10-15 |
| JP6707076B2 (ja) | 2020-06-10 |
| US11992553B2 (en) | 2024-05-28 |
| RU2708397C1 (ru) | 2019-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3185853T3 (da) | Inhalerbare pulverformuleringer af alginatoligomerer | |
| DK3137169T3 (da) | Hæmmere af lysin-specifik demethylase-1 | |
| DK3302565T3 (da) | Faste doseringsformer af palbociclib | |
| DK3157508T3 (da) | Fast oral doseringsform af lipofile forbindelser | |
| DK3851537T5 (da) | Behandling af hyperbilirubinæmi | |
| DK3509581T3 (da) | Formuleringer af (r)-2-amino-3-phenylpropylcarbamat | |
| DK3089741T3 (da) | Farmaceutiske sammensætninger omfattende azd9291 | |
| DK3144001T3 (da) | Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf | |
| HUE055357T2 (hu) | Vegyületek kompozíciói és azok alkalmazásai | |
| DK3116491T3 (da) | Farmaceutiske sammensætninger af terapeutisk aktive forbindelser | |
| IL256322B (en) | Improved formulations of deferasirox and methods of making the same | |
| DK3505209T3 (da) | Pulverinhalator | |
| DK3107548T3 (da) | Tørpulverformuleringer til inhalation | |
| IL248223A0 (en) | Vaccine compositions | |
| DK3220891T3 (da) | Sublingual formulering af riluzol | |
| DK3474822T3 (da) | Formuleringer af brincidofovir | |
| DK3094322T3 (da) | Administration af tasimelteon i fastende tilstand | |
| PL3393451T3 (pl) | Aromatyzowany proszek nikotynowy | |
| DK3418273T3 (da) | Derivater af flavagliner | |
| DK3297619T3 (da) | Terapeutiske anvendelser af L-4-chlorkynurenin | |
| DK3368044T3 (da) | Behandling af hepatisk steatose-relateret oligo-ovulation | |
| DK3697418T3 (da) | Forbedrede formuleringer af bromocriptin | |
| IL254502A0 (en) | Solid forms of menaquinols | |
| DK3201323T3 (da) | Modificering af bakteriofag | |
| DK3129001T3 (da) | Hsp-fri fremstilling af allergen |